Alkermes plc.
- Last sale
- Nov 12, 2026 · -1.90%
- Market cap
- $7.89B
- 168.04M shares
- Filings
- 1,062
Q3 2026−5.2% FY25 yoy
Q3 2026−34.2% FY25 yoy
Q3 2026−39.6% FY25 yoy
Q3 2026derived+18.4% FY25 yoy
Q3 2026−34.1% FY25 yoy
Q3 2026+33.5% FY25 yoy
- $7.89B
- —
- 4.5×
- 4.2×
- 2.88%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,475,899,000 | reported | |
| FY 2024 | 2024-12-31 | $1,557,632,000 | reported | |
| FY 2023 | 2023-12-31 | $1,663,405,000 | reported | |
| FY 2022 | 2022-12-31 | $1,111,795,000 | reported | |
| FY 2021 | 2021-12-31 | $1,173,751,000 | reported | |
| FY 2020 | 2020-12-31 | $1,038,756,000 | reported | |
| FY 2019 | 2019-12-31 | $1,170,947,000 | reported | |
| FY 2018 | 2018-12-31 | $1,094,274,000 | reported | |
| FY 2017 | 2017-12-31 | $903,374,000 | reported | |
| FY 2016 | 2016-12-31 | $745,694,000 | reported | |
| FY 2015 | 2015-12-31 | $628,335,000 | reported | |
| FY 2014 | 2014-12-31 | $618,789,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | — | $200.28M | $200.28M | — | 162.61M sh | −2.7% | 49.4% |
| FY2009 | — | $2.68M | $2.68M | — | — | — | — |
Segments
LineFY2025ShareChange
U.S.$1.37B93%−2.7%
Rest of world$102.36M6.9%−30.0%
Ireland$754.00K0.1%−41.7%
Total$1.48B
Pharmaceutical preparations
Alkermes plc. is the 30th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BPTCTPTC Therapeutics, Inc.$1.7B114.5%39.4%$5.3BPAHCPhibro Animal Health Corp$1.5B17.1%6.6%$1.4B
ALKSAlkermes plc. (this company)$1.5B5.2%16.4%$7.9B
SUPNSupernus, Inc.$1.2B4.3%16.9%$3.4BNSRXNasus Pharma Ltd$1.2B—0.5%$26.6MPBHPrestige Consumer Healthcare Inc.$1.1B4.3%17.5%$2.1BACADAcadia Pharmaceuticals Inc$1.1B11.9%36.5%$3.7BLEGNLegend Biotech Corp$1.0B64.0%28.8%$3.4BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Alkermes plc. · CIK 1520262 · Engraved from SEC EDGAR